Literature DB >> 17136456

No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population.

Jin Eun Choi1, Hyo Gyoung Kang, Myung Hwa Chae, Eun Jin Kim, Won Kee Lee, Sung Ick Cha, Chang Ho Kim, Tae Hoon Jung, Jae Yong Park.   

Abstract

A member of the p53 family, p73 may play an important role in the development of lung cancer. Variations in the DNA sequence in the p73 gene can lead to alterations in the production of p73 and/or activity, which can affect an individual's susceptibility to lung cancer. To test this hypothesis, this study examined the association between the G4C14-to-A4T14 polymorphism in the p73 gene and the risk of lung cancer in a Korean population. The p73 G4C14-to-A4T14 genotypes were determined in 582 lung cancer patients and 582 healthy age- and gender-matched control subjects. Compared with the GC/GC genotype, the GC/AT and the AT/AT genotypes were not significantly associated with the risk of lung cancer [adjusted odds ratio (OR) = 1.08, 95% confidence interval (CI) = 0.84-1.38; and adjusted OR = 1.37, 95% CI = 0.83-2.24, respectively]. In addition, the risk estimate for the combined variant genotype (GC/AT + AT/AT) was similar to that of the GC/GC genotype (a dominant model for the AT allele, adjusted OR = 1.12, 95% CI = 0.88-1.41). These results suggest that the p73 G4C14-to-A4T14 polymorphism does not significantly affect susceptibility to lung cancer in the Korean population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17136456     DOI: 10.1007/s10528-006-9056-8

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  14 in total

Review 1.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  p73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival.

Authors:  Kyung-Eun Lee; Young-Seoub Hong; Byoung-Gwon Kim; Na-Young Kim; Kyoung-Mu Lee; Jong-Young Kwak; Mee-Sook Roh
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

3.  Association of p73 G4C14-A4T14 polymorphisms with genetic susceptibilities to breast cancer: a case-control study.

Authors:  Xin Zhou; Chengyi Wu
Journal:  Med Oncol       Date:  2012-04-26       Impact factor: 3.064

Review 4.  Impact of p73 gene polymorphism on cancer susceptibility: a meta analysis.

Authors:  Yixuan Liu; Weiwei Dong; Quan Mou; Yuxin Leng; Lu Zhang; Liping Duan
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  Association of p73 G4C14-to-A4T14 polymorphism with lung cancer risk.

Authors:  Hua Liu; Yuli Liang; Hua Liao; Lanying Li; Hongyun Wang
Journal:  Tumour Biol       Date:  2014-06-19

6.  Role of p53 and p73 genes polymorphisms in susceptibility to esophageal cancer: a case control study in a northern Indian population.

Authors:  Meenakshi Umar; Rohit Upadhyay; Rohini Khurana; Shaleen Kumar; Uday Chand Ghoshal; Balraj Mittal
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

7.  Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk.

Authors:  Lan Wang; Rui Gao; Long Yu
Journal:  Mol Biol Rep       Date:  2011-05-27       Impact factor: 2.316

8.  Association of p73 gene G4C14-A4T14 polymorphism and MDM2 gene SNP309 with non-small cell lung cancer risk in a Chinese population.

Authors:  Wen Li; Shuang Shuang Wang; Jing Deng; Jian Xin Tang
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

9.  Association of p73 G4C14-to-A4T14 polymorphism with non-small cell lung cancer risk.

Authors:  Shuang Shuang Wang; Xiang Qin Zhu; Shao DI Yang; Lin Li Dong; Wen Li; Jianxin Tang
Journal:  Oncol Lett       Date:  2015-06-04       Impact factor: 2.967

10.  p73 G4C14-to-A4T14 polymorphisms are positively correlated with triple-negative breast cancer in southwestern China.

Authors:  Xin Zhou
Journal:  Med Oncol       Date:  2013-02-27       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.